Basis: Latest stored market observation. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the Price/OCF ratio high or low?
The Price/OCF ratio of 6.47 is in line with its 1-year average of 6.37, around the middle of its 1-year range (6.16–6.64).
As of Thursday, August 27, 2026.
PRICE/OCF RATIO
6.47
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
16.42
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
-60.60%
vs the sector median at left
Market Cap
$105.05B
Price/OCF Ratio
15.49
TTM Avg
13.94
3Y Avg
16.62
5Y Avg
14.00
Market Cap
$125.80B
Price/OCF Ratio
22.50
TTM Avg
26.74
3Y Avg
33.13
5Y Avg
33.02
Market Cap
$86.13B
Price/OCF Ratio
11.65
TTM Avg
13.61
3Y Avg
22.67
5Y Avg
18.29
Market Cap
$131.31B
Price/OCF Ratio
35.50
TTM Avg
54.96
3Y Avg
71.73
5Y Avg
65.19
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sanofi (SNY) | $107.65B | 6.47 | N/A | N/A | N/A |
| McKesson Corporation (MCK)vs › | $105.05B | 15.49 | 13.94 | 16.62 | 14.00 |
| GSK plc (GSK)vs › | $100.70B | 8.74 | 9.25 | 9.27 | 8.47 |
| Medtronic plc (MDT)vs › | $116.98B | 15.81 | 16.20 | 16.58 | 17.60 |
| CVS Health Corp. (CVS)vs › | $119.24B | 8.07 | 11.04 | 9.44 | 8.28 |
| HCA Healthcare, Inc. (HCA)vs › | $90.59B | 8.40 | 8.41 | 8.56 | 10.16 |
| Stryker Corporation (SYK)vs › | $125.80B | 22.50 | 26.74 | 33.13 | 33.02 |
| Elevance Health Inc. (ELV)vs › | $86.13B | 11.65 | 13.61 | 22.67 | 18.29 |
| Intuitive Surgical, Inc. (ISRG)vs › | $131.31B | 35.50 | 54.96 | 71.73 | 65.19 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $81.89B | 19.59 | 15.26 | 19.11 | 17.46 |
P/OCF Ratio
6.5
P/FCF Ratio
7.9
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2026-08-27 | 6.47 |
| 2026-08-26 | 6.56 |
| 2026-08-25 | 6.64 |
| 2026-08-24 | 6.60 |
| 2026-08-21 | 6.62 |
| 2026-08-20 | 6.52 |
| 2026-08-19 | 6.62 |
| 2026-08-18 | 6.49 |
| 2026-08-17 | 6.41 |
| 2026-08-14 | 6.31 |
| 2026-08-13 | 6.32 |
| 2026-08-12 | 6.31 |
| 2026-08-11 | 6.29 |
| 2026-08-10 | 6.28 |
| 2026-08-07 | 6.27 |
| 2026-08-06 | 6.19 |
| 2026-08-05 | 6.18 |
| 2026-08-04 | 6.16 |
| 2026-08-03 | 6.20 |
| 2026-07-31 | 6.22 |
| 2026-07-30 | 6.19 |
